Drugs / Recombinant Poliomyelitis Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07688369 | Jul → Nov 2026 expected | poliomyelitis | Serum Institute of India Pvt. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Poliomyelitis Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07688369 ↗ |
| Known as | rPV | “Recombinant Poliomyelitis Vaccine (rPV)” NCT07688369 ↗ |
| Modality | Vaccine | “Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd.” NCT07688369 ↗ |
| Route | Intramuscular | “The study vaccine will be administered as a single intramuscular (IM) injection into the deltoid muscle of the non-dominant upper arm.” NCT07688369 ↗ |